Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804255 | 0.93 | FFAR4 (0.42) | FFAR4FFAR1CYP4F2CYP4A11MEN1 | |
| SCHEMBL19804104 | 0.93 | FFAR4 (0.43) | FFAR4FFAR1CYP4F2CYP4A11SLC5A1 | |
| SCHEMBL19804346 | 0.90 | FFAR4 (0.40) | FFAR4FFAR1MEN1KMT2ACA1 | |
| SCHEMBL19804250 | 0.89 | FFAR4 (0.38) | FFAR4FFAR1CYP4F2CYP4A11CA1 | |
| SCHEMBL19804201 | 0.89 | FFAR4 (0.41) | FFAR4FFAR1MEN1KMT2A | |
| SCHEMBL19804014 | 0.88 | FFAR4 (0.37) | FFAR4FFAR1CYP4F2CYP4A11MEN1 | |
| SCHEMBL19796408 | 0.87 | CYP4F2 (0.38) | FFAR4FFAR1CYP4F2CYP4A11 | |
| SCHEMBL19796331 | 0.87 | CYP4F2 (0.38) | FFAR4FFAR1CYP4F2CYP4A11 | |
| SCHEMBL19804282 | 0.86 | FFAR4 (0.42) | FFAR4FFAR1CYP4F2CYP4A11CA1 | |
| SCHEMBL19804668 | 0.86 | FFAR1 (0.42) | FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | FFAR4 1715/4885FFAR1 1057/4885CYP4F2 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.